NSCLC Immunotherapy: Clinical Management

Jointly provided by Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.

This activity is supported by an independent education grant from AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, Merck &Co., Inc.

Scroll to the Bottom of this Information to Begin this Course

Release date: October 31, 2016

Valid through: July 31, 2017

Specialty: Physicians and Registered Nurses

Topic: Immunotherapy

Media: Internet

Estimated Time to Complete Activity: 30 minutes

Target Audience

This activity has been designed to meet the educational needs of Physicians and Registered Nurses involved in the care of patients with non-small cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the key mechanisms and terminology of tumor immunology and cancer immunotherapy.
  • Identify the current immunotherapy treatments for non-small cell lung cancer; including their mechanism of action, adverse events, clinical management, and efficacy.
  • Incorporate immunotherapy in treatment regimens.
  • Differentiate the side effects between immunotherapy treatments and traditional treatments for NSCLC in monitoring and educating.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit

All other healthcare professionals completing this course will be issued a statement of participation.

Faculty

Maura Abbott, PhD, AOCNP, CPNP

Assistant Professor of Nursing, Oncology Program Director
Columbia University Medical Center

Jarushka Naidoo, MD

Assistant Professor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Maura Abbott, PhD, AOCNP, CPNP
  • No relevant financial relationships to disclose.
Jarushka Naidoo, MD
  • No relevant financial relationships to disclose.

The steering committee reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Julie Brahmer, MD
  • Consulting Fees: Merck, BMS (non-compensated), Eli Lilly, Celgene
    Contracted Research: BMS; MedImmune/AstraZeneca; Merck
Ann Lau Clark, RN, MSN, CCRP, CCRC
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (ie: Speakers’ Bureau): BMS and Merck
Roy Herbst, MD, PhD
  • Consulting Fees: Biothera; Diatech; Kolltan
    Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agent (ie: Speakers’ Bureau): AstraZeneca; Boehringer Ingelheim; Eli Lilly; Genentech/Roche; Merck; Pfizer
  • Contracted Research: Genentech; Merck
Naiyer Rizvi, MD
  • Consulting Fees: AstraZeneca; Roche; Novartis; Merck
  • Ownership Interest: Gristone Oncology
Tanguy Seiwert, MD
  • Consulting Fees: Amgen; AstraZeneca; BMS; Celgene; Merck/MSD; Merck Serono; Jounce
David Spigel, MD
  • No relevant financial relationships to disclose.

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following SITC planners and managers, Tara Withington, CAE, Mike Scorzo, Ed.D., and Lianne Wiggins hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months

Instructions for Participation and Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must read the learning objectives and faculty disclosures; study the educational activity; and complete the post-test and the evaluation form. If you pass the post-test and complete the evaluation, your certificate will be available immediately for download in PDF format.

Hardware and Software Requirements

his site is best viewed with an HTML5 compatible browser; this list includes the versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Supplemental Video Here